Clinical Trial Update: STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 [Phase 2]

View source ↗

Summary

This Phase 2, single-arm trial evaluating tiragolumab plus ivonescimab for lung squamous cell carcinoma in patients who progressed on platinum doublets and anti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Squamous Cell Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Squamous Cell Carcinoma, Anti-PD1/PDL1 Antibody | Phase 2 | Status: WITHDRAWN